期刊文献+

HPLC法测定利福昔明的含量与有关物质 被引量:2

Content assay of rifaximin and its related substances by HPLC
下载PDF
导出
摘要 目的建立利福昔明含量和有关物质的HPLC测定法。方法使用Resolve C18柱(150mm×5.0mm,5μm);柱温40℃;流动相:甲醇∶乙腈∶0.05mol/L磷酸二氢钾溶液∶0.5mol/L柠檬酸溶液(15∶30∶26∶4);流速1ml/min;检测波长254nm;进样量20μl。结果利福昔明在浓度为0.2-0.05mg/ml范围内呈很好的线性关系,r=0.9999,重复性和日内精密度RSD分别为0.25%(n=5)和0.83%(n=6)。结论该方法简单、准确、专属性强,可用于利福昔明含量及有关物质的测定。 Objective To establish an HPLC method for the determination of content of rifaximin and its related substances. Methods A Resolve C18 column (150mm×5.0mm, 5μm) was used; the temperature of column: 40℃; mobile phase: methanol : acetomitrile : 0.05mgl/L potassium dihydrogen phosphate solution-and 0. 5mol/L citric acid solution (15 : 30 : 26 : 4); flow rate: 1.0ml/min; wavelength: 254nm; the injection volume was 20μl. Results The linear range for rifaximin was 0.2mg-0.05mg/ml (r=0. 9999), repeatability and the inter-day precision RSD was 0.25% (n=5) and 0.83% (n=6). Conclusion The method was convenient, specific, accurate and can be used for determinatim of rifaximin and its related s ubstances.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2007年第2期89-90,103,共3页 Chinese Journal of Antibiotics
关键词 利福昔明 含量测定 有关物质 高效液相色谱法 Rifaximin Content assay Related substances HPLC
  • 相关文献

参考文献4

二级参考文献15

  • 1Jiang Z D, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration[J] Antimicrob Agents Chemother ,2000,44(8):2205
  • 2Dupont H L, Jiang Z D, Ericsson C D, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial [J]. Clin Infect Dis,2001,33(11): 1807
  • 3Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind,double-dummy, controlled clinical trial [J]. J Hepatol,2003; 38(1): 51
  • 4Lawler J V, Wallace M R. Diagnosis and treatment of bacterial diarrhea [J]. Curr Gastroenterol Rep,2003,5 (4):287
  • 5Tursi A. Acute diverticulitis of the colon--current medical therapeutic management [J]. Expert Opin Pharmacother,2004,5(1) :55
  • 6Jiang Z D,Ke S,Palazzini E,et al.In vitro activity and fecal concentration of rifaximin after oral administration[J].Antimicrob Agents Chemother,2000,44 (8):2205
  • 7Descombe J J,Dubourg D,Picard M,et al.Pharmacokinetic study of rifaximin after oral administration in healthy volunteers [J].Int J Clin Pharmacol Res,1994,14(2):51
  • 8Rizzello F,Gionchetti P,Venturi A,et al.Rifaximin systemic absorption in patients with ulcerative colitis [J].Eur J Clin Pharmaco1,1998,54(1) :91
  • 9Gionchetti P,Rizzello F,Ferrieri A,et al.Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment:a double blind placebo-controlled trial [J].Dig Dis Sci,1999,44(6):1220
  • 10Hoover W W,Gerlach E H,Hoban D J,et al.Antimicrobial activity and spectrum of rifaximin a new topical rifamycin derivative [J].Diagn Microbiol Infect Dis,1993,16(2):111

共引文献12

同被引文献21

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部